Nilda  Mesa net worth and biography

Nilda Mesa Biography and Net Worth

Director of United Therapeutics
Professor Mesa has had a long and innovative career in environment, energy, and sustainability at the city, state, national, and global levels, and now writes and presents extensively on climate, energy, equity, and urban systems relating to them. From 2014 to 2016, Professor Mesa served as Director of the New York City Mayor’s Office of Sustainability, where she led the pathbreaking OneNYC long-term sustainability plan for the city. As chief sustainability officer for New York City, she oversaw programs in climate, energy, sustainability, air quality and public health, waste, green buildings, transportation, public education, and other initiatives. In 2016, she returned to Columbia University as an adjunct professor at the School of International and Public Affairs, as well as Director of the Urban Sustainability and Equity Planning Program with Columbia’s Center for Sustainable Urban Development at the Earth Institute. She is currently Adjunct Professor in the Graduate School of Architecture, Planning, and Preservation. In 2006, she founded Columbia’s Office of Environmental Stewardship, one of the first in the United States for a university. She also served as Chief Administrative Officer at the Columbia Journalism School from 2012 to 2014. Before joining Columbia, Professor Mesa served in environmental leadership roles at the White House Council on Environmental Quality, the U.S. Air Force, the U.S. Environmental Protection Agency, and the California Attorney General’s office, and practiced law in both the public and private sectors. Her work has involved extensive international experience, including most recently a 2018 to 2021 appointment as a visiting professor and lecturer at the Paris School of International Affairs at SciencesPo (Paris Institute of Political Studies), an international research university in France. She is the co-author of Collaborating for Climate Resilience (Routledge, 2021), and a contributor to Smarter New York City: How City Agencies Innovate (Columbia University Press, 2019). She is a graduate of Harvard Law School and Northwestern University.

What is Nilda Mesa's net worth?

The estimated net worth of Nilda Mesa is at least $1.29 million as of December 19th, 2023. Ms. Mesa owns 5,698 shares of United Therapeutics stock worth more than $1,293,617 as of February 25th. This net worth approximation does not reflect any other assets that Ms. Mesa may own. Learn More about Nilda Mesa's net worth.

How do I contact Nilda Mesa?

The corporate mailing address for Ms. Mesa and other United Therapeutics executives is 1040 SPRING ST, SILVER SPRING MD, 20910. United Therapeutics can also be reached via phone at (301) 608-9292 and via email at [email protected]. Learn More on Nilda Mesa's contact information.

Has Nilda Mesa been buying or selling shares of United Therapeutics?

Nilda Mesa has not been actively trading shares of United Therapeutics during the last ninety days. Most recently, Nilda Mesa sold 605 shares of the business's stock in a transaction on Tuesday, December 19th. The shares were sold at an average price of $244.90, for a transaction totalling $148,164.50. Following the completion of the sale, the director now directly owns 5,698 shares of the company's stock, valued at $1,395,440.20. Learn More on Nilda Mesa's trading history.

Who are United Therapeutics' active insiders?

United Therapeutics' insider roster includes Christopher Causey (Director), Raymond Dwek (Director), Paul Mahon (EVP), Nilda Mesa (Director), Judy Olian (Director), Christopher Patusky (Director), Martine Rothblatt (CEO), and Louis Sullivan (Director). Learn More on United Therapeutics' active insiders.

Are insiders buying or selling shares of United Therapeutics?

During the last twelve months, United Therapeutics insiders bought shares 1 times. They purchased a total of 6 shares worth more than $684.36. During the last twelve months, insiders at the biotechnology company sold shares 47 times. They sold a total of 294,867 shares worth more than $66,627,060.87. The most recent insider tranaction occured on February, 15th when EVP Paul A Mahon sold 6,000 shares worth more than $1,291,860.00. Insiders at United Therapeutics own 12.5% of the company. Learn More about insider trades at United Therapeutics.

Information on this page was last updated on 2/15/2024.

Nilda Mesa Insider Trading History at United Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/19/2023Sell605$244.90$148,164.505,698View SEC Filing Icon  
9/13/2023Sell383$222.36$85,163.886,303View SEC Filing Icon  
5/5/2023Sell374$214.81$80,338.945,806View SEC Filing Icon  
11/7/2022Sell290$268.57$77,885.306,180View SEC Filing Icon  
9/28/2022Sell850$211.05$179,392.506,870View SEC Filing Icon  
See Full Table

Nilda Mesa Buying and Selling Activity at United Therapeutics

This chart shows Nilda Mesa's buying and selling at United Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

United Therapeutics Company Overview

United Therapeutics logo
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and TETON studies, which are the studies of Tyvaso for the treatment of idiopathic pulmonary fibrosis. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Read More

Today's Range

Now: $227.50
Low: $225.18
High: $228.57

50 Day Range

MA: $219.64
Low: $210.76
High: $246.40

2 Week Range

Now: $227.50
Low: $204.44
High: $261.54

Volume

25,710 shs

Average Volume

340,025 shs

Market Capitalization

$10.71 billion

P/E Ratio

11.47

Dividend Yield

N/A

Beta

0.52
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Full details and steps to take here.